Browse Arkansas Code titles and sections
21 U.S.C. § 361 — Adulterated cosmetics
Federal law — U.S. Code and appendices · legal_authorities
Page 480
TITLE 21—FOOD AND DRUGS
§ 360fff–7
505G(b) of the Federal Food, Drug, and Cosmetic Act [21
U.S.C. 355h(b)], as added by section 3851 of this subtitle,
with respect to a drug that was the subject of an appli-
cation extinguished under paragraph (1).’’
§ 360fff–7. Report
(a) In general
(1) In general
Not later than 18 months after November 26,
2014, and on the dates that are 2 and 4 years
thereafter, the Secretary shall issue a report
to the Committee on Health, Education,
Labor, and Pensions of the Senate and the
Committee on Energy and Commerce of the
House of Representatives describing actions
taken under this part.
(2) Contents
The reports under this subsection shall in-
clude—
(A) a review of the progress made in
issuing GRASE determinations for pending
requests, including the number of pending
requests—
(i) reviewed and the decision times for
each request, measured from the date of
the original request for an eligibility de-
termination submitted by the sponsor;
(ii) resulting in a determination that the
nonprescription sunscreen active ingre-
dient or combination of nonprescription
sunscreen active ingredients is GRASE and
is not misbranded;
(iii) resulting in a determination that
the nonprescription sunscreen active in-
gredient or combination of nonprescrip-
tion sunscreen active ingredients is not
GRASE and is misbranded and the reasons
for such determinations; and
(iv) for which a determination has not
been made, and an explanation for the
delay, a description of the current status
of each such request, and the length of
time each such request has been pending,
measured from the date of original request
for an eligibility determination by the
sponsor;
(B) a review of the progress made in
issuing GRASE determinations
Source: Supplied 2024 U.S. Code historical extraction · 21 U.S.C. § 361
Stored review status: historical_2024_not_currentness_verified. A text match is a research starting point; applicability is not established.
Original supplied file — preserved unchanged
Download original Markdown file
File SHA-256: b1e4a6bd200b65affc78cea2e43ab5c39769633f7304f5b221aa5ecaa4994b02. The original may include catalog metadata, neighboring provisions, or embedded records outside this collection's scope. Search shows only the selected federal record. Historical editions and unverified snapshots are not a statement of current law.
Authority boundary: historical or unconfirmed source not current law verified.
Open the recorded source website ↗
Record provenance
Stable record: federal_law:legal_authorities:usc2024-6c163fe77e70e80e3a5e91c9
Source file: Laws/federal/codes/united-states-code-2024/title-21/section-361-adulterated-cosmetics--57edb74209.md
Pages: Not recorded – Not recorded
Passage SHA-256: 308635f5a4af01640ee14bc28eb5273fb7159c1f83096576cb4d97ffa215f4be
Source location: USCODE-2024-title21-chap9-subchapVI-sec361.pdf
Stored source content
Page 480
TITLE 21—FOOD AND DRUGS
§ 360fff–7
505G(b) of the Federal Food, Drug, and Cosmetic Act [21
U.S.C. 355h(b)], as added by section 3851 of this subtitle,
with respect to a drug that was the subject of an appli-
cation extinguished under paragraph (1).’’
§ 360fff–7. Report
(a) In general
(1) In general
Not later than 18 months after November 26,
2014, and on the dates that are 2 and 4 years
thereafter, the Secretary shall issue a report
to the Committee on Health, Education,
Labor, and Pensions of the Senate and the
Committee on Energy and Commerce of the
House of Representatives describing actions
taken under this part.
(2) Contents
The reports under this subsection shall in-
clude—
(A) a review of the progress made in
issuing GRASE determinations for pending
requests, including the number of pending
requests—
(i) reviewed and the decision times for
each request, measured from the date of
the original request for an eligibility de-
termination submitted by the sponsor;
(ii) resulting in a determination that the
nonprescription sunscreen active ingre-
dient or combination of nonprescription
sunscreen active ingredients is GRASE and
is not misbranded;
(iii) resulting in a determination that
the nonprescription sunscreen active in-
gredient or combination of nonprescrip-
tion sunscreen active ingredients is not
GRASE and is misbranded and the reasons
for such determinations; and
(iv) for which a determination has not
been made, and an explanation for the
delay, a description of the current status
of each such request, and the length of
time each such request has been pending,
measured from the date of original request
for an eligibility determination by the
sponsor;
(B) a review of the progress made in
issuing GRASE determinations for requests
not included in the reporting under subpara-
graph (A), including the number of such re-
quests—
(i) reviewed and the decision times for
each request;
(ii) resulting in a determination that the
nonprescription sunscreen active ingre-
dient, combination of nonprescription sun-
screen active ingredients, or other ingre-
dient is GRASE and is not misbranded;
(iii) resulting in a determination that
the nonprescription sunscreen active in-
gredient, combination of nonprescription
sunscreen active ingredients, or other in-
gredient is not GRASE and is misbranded
and the reasons for such determinations;
and
(iv) for which a determination has not
been made, and an explanation for the
delay, a description of the current status
of each such request, and the length of
time each such request has been pending,
measured from the date of original request
for an eligibility determination by the
sponsor;
(C) an annual accounting (including infor-
mation from years prior to November 26,
2014, where such information is available) of
the total number of requests submitted,
pending, or completed under this part, in-
cluding whether such requests were the sub-
ject of an advisory committee convened by
the Secretary;
(D) a description of the staffing and re-
sources relating to the costs associated with
the review and decisionmaking pertaining to
requests under this part;
(E) a review of the progress made in meet-
ing the deadlines with respect to processing
requests under this part; and
(F) to the extent the Secretary determines
appropriate, recommendations for process
improvements in the handling of requests
under this part, including the advisory com-
mittee review process.
(b) Method
The Secretary shall publish the reports under
subsection (a) in the manner the Secretary de-
termines to be the most effective for efficiently
disseminating the report, including publication
of the report on the Internet website of the Food
and Drug Administration.
(June 25, 1938, ch. 675, § 586G, as added Pub. L.
113–195, § 4(c), Nov. 26, 2014, 128 Stat. 2050.)
§ 360fff–8. Sunset
This part shall cease to be effective at the end
of fiscal year 2022.
(June 25, 1938, ch. 675, § 586H, as added Pub. L.
116–136, div. A, title III, § 3854(b)(4), Mar. 27, 2020,
134 Stat. 456.)
SUBCHAPTER VI—COSMETICS
§ 361. Adulterated cosmetics
A cosmetic shall be deemed to be adulter-
ated—
(a) If it bears or contains any poisonous or del-
eterious substance which may render it inju-
rious to users under the conditions of use pre-
scribed in the labeling thereof, or under such
conditions of use as are customary or usual, ex-
cept that this provision shall not apply to coal-
tar hair dye, the label of which bears the fol-
lowing legend conspicuously displayed thereon:
‘‘Caution—This product contains ingredients
which may cause skin irritation on certain indi-
viduals and a preliminary test according to ac-
companying directions should first be made.
This product must not be used for dyeing the
eyelashes or eyebrows; to do so may cause blind-
ness.’’, and the labeling of which bears adequate
directions for such preliminary testing. For the
purposes of this paragraph and paragraph (e) the
term ‘‘hair dye’’ shall not include eyelash dyes
or eyebrow dyes.
(b) If it consists in whole or in part of any
filthy, putrid, or decomposed substance.
(c) If it has been prepared, packed, or held
under insanitary conditions whereby it may
Page 481
TITLE 21—FOOD AND DRUGS
§ 362
1 So in original. Probably should be ‘‘of’’.
have become contaminated with filth, or where-
by it may have been rendered injurious to
health.
(d) If its container is composed, in whole or in
part, of any poisonous or deleterious substance
which may render the contents injurious to
health.
(e) If it is not a hair dye and it is, or it bears
or contains, a color additive which is unsafe
within the meaning of section 379e(a) of this
title.
(f) If it has been manufactured or processed
under conditions that do not meet the good
manufacturing practice requirements of section
364b of this title.
(g) If it is a cosmetic product, and the cos-
metic product, including each ingredient in the
cosmetic product, does not have adequate sub-
stantiation for 1 safety, as defined in section
364d(c) of this title.
(June 25, 1938, ch. 675, § 601, 52 Stat. 1054; Pub. L.
86–618, title I, § 102(c)(1), July 12, 1960, 74 Stat.
398; Pub. L. 102–571, title I, § 107(11), Oct. 29, 1992,
106 Stat. 4499; Pub. L. 103–80, § 3(x), Aug. 13, 1993,
107 Stat. 778; Pub. L. 117–328, div. FF, title III,
§ 3503(a)(2), Dec. 29, 2022, 136 Stat. 5858.)
Editorial Notes
AMENDMENTS
2022—Subsecs. (f), (g). Pub. L. 117–328 added subsecs.
(f) and (g).
1993—Subsec. (a). Pub. L. 103–80 substituted ‘‘usual,
except that this’’ for ‘‘usual: Provided, That this’’.
1992—Par. (e). Pub. L. 102–571 substituted ‘‘379e(a)’’ for
‘‘376(a)’’.
1960—Par. (e). Pub. L. 86–618 substituted ‘‘and it is, or
it bears or contains, a color additive which is unsafe
within the meaning of section 376(a) of this title’’ for
‘‘and it bears or contains a coal-tar color other than
one from a batch that has been certified in accordance
with regulations as provided by section 364 of this
title’’.
Statutory Notes and Related Subsidiaries
EFFECTIVE DATE OF 2022 AMENDMENT
Amendment by Pub. L. 117–328 effective on the date
that is 1 year after Dec. 29, 2022, see section 3503(b)(1)
of Pub. L. 117–328, set out as a note under section 331 of
this title.
EFFECTIVE DATE OF 1960 AMENDMENT
Amendment by Pub. L. 86–618 effective July 12, 1960,
subject to the provisions of section 203 of Pub. L. 86–618,
see section 202 of Pub. L. 86–618, set out as a note under
section 379e of this title.
EFFECTIVE DATE; POSTPONEMENT
Par. (e) effective Jan. 1, 1940, see act June 23, 1939, ch.
242, 53 Stat. 853, set out as an Effective Date; Postpone-
ment in Certain Cases note under section 301 of this
title.
EFFECTIVE DATE
Section effective twelve months after June 25, 1938,
except par. (a), which, with certain exceptions, became
effective on June 25, 1938, see section 1002(a) of act June
25, 1938, set out as a note under section 301 of this title.
CONSTRUCTION; CONFIDENTIALITY
Nothing in amendment made by Pub. L. 117–328, to be
construed to authorize the disclosure of information
that is prohibited from disclosure under section 331(j)
of this title or section 1905 of title 18 or that is subject
to withholding under section 552(b)(4) of title 5, see sec-
tion 3503(c)(2) of Pub. L. 117–328, set out as a note under
section 364 of this title.
§ 362. Misbranded cosmetics
A cosmetic shall be deemed to be mis-
branded—
(a) If its labeling is false or misleading in any
particular.
(b) If in package form unless it bears a label
containing (1) the name and place of business of
the manufacturer, packer, or distributor; (2) an
accurate statement of the quantity of the con-
tents in terms of weight, measure, or numerical
count; and (3) the information required under
section 364e of this title: Provided, That under
clause (2) of this paragraph reasonable vari-
ations shall be permitted, and exemptions as to
small packages shall be established, by regula-
tions prescribed by the Secretary.
(c) If any word, statement, or other informa-
tion required by or under authority of this chap-
ter to appear on the label or labeling is not
prominently placed thereon with such conspicu-
ousness (as compared with other words, state-
ments, designs, or devices, in the labeling) and
in such terms as to render it likely to be read
and understood by the ordinary individual under
customary conditions of purchase and use.
(d) If its container is so made, formed, or filled
as to be misleading.
(e) If it is a color additive, unless its pack-
aging and labeling are in conformity with such
packaging and labeling requirements, applicable
to such color additive, as may be contained in
regulations issued under section 379e of this
title. This paragraph shall not apply to pack-
ages of color additives which, with respect to
their use for cosmetics, are marketed and in-
tended for use only in or on hair dyes (as defined
in the last sentence of section 361(a) of this
title).
(f) If its packaging or labeling is in violation
of an applicable regulation issued pursuant to
section 1472 or 1473 of title 15.
(June 25, 1938, ch. 675, § 602, 52 Stat. 1054; Pub. L.
86–618, title I, § 102(c)(2), July 12, 1960, 74 Stat.
398; Pub. L. 91–601, § 6(f), formerly § 7(f), Dec. 30,
1970, 84 Stat. 1673, renumbered Pub. L. 97–35,
title XII, § 1205(c), Aug. 13, 1981, 95 Stat. 716; Pub.
L. 102–571, title I, § 107(12), Oct. 29, 1992, 106 Stat.
4499; Pub. L. 117–328, div. FF, title III, § 3503(a)(3),
Dec. 29, 2022, 136 Stat. 5858.)
Editorial Notes
AMENDMENTS
2022—Subsec. (b)(3). Pub. L. 117–328 added par. (3) be-
fore proviso.
1992—Par. (e). Pub. L. 102–571 substituted ‘‘379e’’ for
‘‘376’’.
1970—Par. (f). Pub. L. 91–601 added par. (f).
1960—Par. (e). Pub. L. 86–618 added par. (e).
Statutory Notes and Related Subsidiaries
EFFECTIVE DATE OF 2022 AMENDMENT
Amendment by Pub. L. 117–328 effective on the date
that is 1 year after Dec. 29, 2022, see section 3503(b)(1)
of Pub. L. 117–328, set out as a note under section 331 of
this title.
Cross-references
Connections may be documented source relationships, shared citations or nearby passages. Each explains its basis; a connection alone does not establish applicability to your situation.
Federal law — U.S. Code and appendices · legal_authorities
**(a) Nonprescription drugs marketed without an approved application** Nonprescription drugs marketed without an approved drug application under [section 355 of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section355&num=0&edition=prelim), as of March 27, 2020, shall be treated in accordance with this subsection.
(1) **Drugs subject to a final monograph; category I drugs subject to a tentative final monograph** — A drug is deemed to be generally recognized as safe and effective under [section 321(p)(1) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321/p/1&num=0&edition=prelim), not a new drug under [section 321(p) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321/p&num=0&edition=prelim), and not subject to [section 353(b)(1) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section353/b/1&num=0&edition=prelim), if—
(A) the drug is—
(i) in conformity with the requirements for nonprescription use of a final monograph issued under part 330 of title 21, Code of Federal Regulations (except as provided in paragraph (2)), the general requirements for nonprescription drugs, and conditions or requirements under subsections (b), (c), and (k); and
(ii) except as permitted by an order issued under subsection (b) or, in the case of a minor change in the drug, in conformity with an order issued under subsection (c), in a dosage form that, immediately prior to March 27, 2020, has been used to a material extent and for a material time under [section 321(p)(2) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section321/p/2&num=0&edition=prelim); or
(B) the drug is—
(i) clas
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 355h
Stored review status: release_metadata_unconfirmed. The source passage cites 21 U.S.C. § 355h. This identifies an authority to review, not proof of applicability.
Federal law — U.S. Code and appendices · legal_authorities
Page 263
TITLE 21—FOOD AND DRUGS
§ 355h
(3) not later than 18 months after the close
of the public comment period for the draft
guidance described in paragraph (2), issue re-
vised draft guidance or final guidance.
(f) Rule of construction
(1) In general
Subject to paragraph (2), nothing in this sec-
tion prohibits the Secretary from using real
world evidence for purposes not specified in
this section, provided the Secretary deter-
mines that sufficient basis exists for any such
nonspecified use.
(2) Standards of evidence and Secretary’s au-
thority
This section shall not be construed to alter—
(A) the standards of evidence under—
(i) subsection (c) or (d) of section 355 of
this title, including the substantial evi-
dence standard in such subsection (d); or
(ii) section 262(a) of title 42; or
(B) the Secretary’s authority to require
postapproval studies or clinical trials, or the
standards of evidence under which studies or
trials are evaluated.
(June 25, 1938, ch. 675, § 505F, as added Pub. L.
114–255, div. A, title III, § 3022, Dec. 13, 2016, 130
Stat. 1096; amended Pub. L. 115–52, title IX,
§ 901(c), (d), Aug. 18, 2017, 131 Stat. 1076.)
Editorial Notes
AMENDMENTS
2017—Subsec. (b). Pub. L. 115–52, § 901(c), substituted
‘‘traditional’’ for ‘‘randomized’’.
Subsec. (d). Pub. L. 115–52, § 901(d), substituted ‘‘3
years’’ for ‘‘2 years’’.
§ 355h. Regulation of certain nonprescription
drugs that are marketed without an ap-
proved drug application
(a) Nonprescription drugs marketed without an
approved application
Nonprescription drugs marketed without an
approved drug application under section 355 of
this title, as of March 27, 2020, shall be treated
in accordance with this subsection.
(1) Drugs subject to a final monograph; cat-
egory I drug
Source: Supplied 2024 U.S. Code historical extraction · 21 U.S.C. § 355h
Stored review status: historical_2024_not_currentness_verified. The source passage cites 21 U.S.C. § 355h. This identifies an authority to review, not proof of applicability.
Federal law — U.S. Code and appendices · legal_authorities
A cosmetic shall be deemed to be adulterated—
**(a)** If it bears or contains any poisonous or deleterious substance which may render it injurious to users under the conditions of use prescribed in the labeling thereof, or under such conditions of use as are customary or usual, except that this provision shall not apply to coal-tar hair dye, the label of which bears the following legend conspicuously displayed thereon: “Caution—This product contains ingredients which may cause skin irritation on certain individuals and a preliminary test according to accompanying directions should first be made. This product must not be used for dyeing the eyelashes or eyebrows; to do so may cause blindness.”, and the labeling of which bears adequate directions for such preliminary testing. For the purposes of this paragraph and paragraph (e) the term “hair dye” shall not include eyelash dyes or eyebrow dyes.
**(b)** If it consists in whole or in part of any filthy, putrid, or decomposed substance.
**(c)** If it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health.
**(d)** If its container is composed, in whole or in part, of any poisonous or deleterious substance which may render the contents injurious to health.
**(e)** If it is not a hair dye and it is, or it bears or contains, a color additive which is unsafe within the meaning of [section 379e(a) of this title](https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section379e/a&num=0&edition=prelim).
**(f)** If it has been manufactured or processed under conditions that do not meet the good manufacturing practice requirements of [section 364b of this title](https://uscode.house.gov/view.xhtml?r
Source: Supplied U.S. Code snapshot — release unconfirmed · 21 U.S.C. § 361
Stored review status: release_metadata_unconfirmed. Same stored citation; legal effect and authority still require review.